Earnings summaries and quarterly performance for RxSight.
Executive leadership at RxSight.
Board of directors at RxSight.
Research analysts who have asked questions during RxSight earnings calls.
Thomas Stephan
Stifel
4 questions for RXST
Also covers: ALC, GKOS, SGHT +1 more
David Saxon
Needham & Company
3 questions for RXST
Also covers: ALC, ALGN, ATEC +11 more
Steven Lichtman
Oppenheimer & Co. Inc.
3 questions for RXST
Also covers: ALC, ANGO, COO +12 more
Craig Bijou
Bank of America Securities
2 questions for RXST
Also covers: BLCO, COO, FNA +9 more
Lei Huang
Wells Fargo
2 questions for RXST
Also covers: NVCR, PEN, SOLV
Lilia-Celine Lozada
JPMorgan Chase & Co.
2 questions for RXST
Also covers: ATRC, BVS, CBLL +4 more
Robert Marcus
JPMorgan Chase & Co.
2 questions for RXST
Also covers: ABT, BAX, BDX +21 more
Young Li
Jefferies
2 questions for RXST
Also covers: ALC, ARAY, ATEC +8 more
Adam Maeder
Piper Sandler Companies
1 question for RXST
Also covers: ABT, AXNX, EW +13 more
Angela Runyararo Kumirai
UBS Group
1 question for RXST
Danielle Antalffy
UBS Group AG
1 question for RXST
Also covers: ABT, ATRC, BAX +15 more
Larry Biegelsen
Wells Fargo & Company
1 question for RXST
Also covers: ABT, ALC, AXNX +24 more
Patrick Wood
Morgan Stanley
1 question for RXST
Also covers: ALC, BDX, BLCO +17 more
Ryan Zimmerman
BTIG
1 question for RXST
Also covers: ALC, GEHC, GKOS +23 more
Simran Kaur
Wells Fargo & Company
1 question for RXST
Also covers: HYPR, PODD
Recent press releases and 8-K filings for RXST.
RxSight Discusses 2025 Challenges and 2026 Outlook at Piper Sandler Conference
RXST
Guidance Update
Demand Weakening
New Projects/Investments
- RxSight experienced "bumps along the way" in 2025, including an early-year contraction in the general cataract market and increased competition from new presbyopia correcting IOLs. The company's focus has shifted from growing its installed base to driving utilization growth (same-store sales) within its existing customer accounts.
- The implied Q4 guidance indicates a sequential revenue step down, which is unusual for a historically strong quarter, attributed to conservatism and a business pivot. For 2026, while no official guidance has been given, RxSight expects sequential quarter-over-quarter growth, subject to seasonality, with the street modeling $135 million in revenue.
- International expansion is an evolving focus, with a new VP of International hired and recent approvals in the EU and Korea. A more material revenue contribution from international markets is anticipated in 2027, with 2026 serving as a build-up year.
3 days ago
RxSight discusses 2025 challenges, Q4 guidance, and 2026 outlook
RXST
Guidance Update
Demand Weakening
New Projects/Investments
- RxSight experienced challenges in 2025, including a contracted cataract market and increased competitive IOL introductions, leading the company to pivot its focus towards utilization growth within its existing customer base.
- The company anticipates an implied sequential revenue step down for Q4 2025, noting a conservative approach and a business pivot.
- For 2026, RxSight expects sequential growth quarter-over-quarter, subject to seasonality, with the street modeling $135 million in revenue.
- RxSight is expanding internationally, having hired a VP of International and secured approvals in the EU and several Asian countries, with material revenue contribution from these efforts expected in 2027.
3 days ago
RxSight Discusses 2025 Challenges, 2026 Outlook, and Growth Strategy
RXST
Guidance Update
New Projects/Investments
Demand Weakening
- RxSight faced challenges in 2025 including a contracted cataract market and increased competition from new presbyopia-correcting IOLs, leading to a pivot in strategy to focus on utilization growth within existing customers. The company's second-half guidance for 2025 is positioned at $56 million at the mid-point.
- For 2026, RxSight expects sequential revenue growth quarter-over-quarter, subject to seasonality, and is investing more in sales and marketing and R&D to drive growth. The street is modeling $135 million of revenue for 2026.
- The company views international expansion as a significant opportunity, targeting 20 countries with a market potential of $26 billion to $27 billion, which is double the U.S. opportunity. Material revenue contribution from international markets is anticipated to be a 2027 story, following a build-up in 2026.
- RxSight's LAL technology is considered unique and differentiated, currently holding about 10% of the premium IOL space, with no direct near-term competition foreseen.
3 days ago
RxSight Reports Q3 2025 Financial Results and Updates Full-Year Guidance
RXST
Earnings
Guidance Update
Demand Weakening
- RxSight reported Q3 2025 revenue of $30.3 million, a 14% decrease year-over-year, with LAL revenue at $25.7 million from 26,045 units sold. The company achieved a gross margin of 79.9% and a GAAP net loss of $9.8 million, or $0.24 per share.
- The LDD installed base grew to 1,109 units as of September 30, 2025, a 25% increase year-over-year, while LDD sales in Q3 2025 were 25 units, a 68% decrease from the prior year. Approximately 2,000 ophthalmologists implanted the Light Adjustable Lens during the quarter.
- For the full year 2025, RxSight narrowed its revenue guidance to $125 million-$130 million and increased its gross margin guidance to 76%-77%. Operating expenses guidance was reiterated at $145 million-$155 million.
- RxSight ended Q3 2025 with $227.5 million in cash and short-term investments.
Nov 5, 2025, 9:30 PM
RxSight Reports Q3 2025 Financial Results
RXST
Earnings
Guidance Update
Demand Weakening
- RxSight, Inc. reported Q3 2025 revenue of $30.3 million, a 14% decrease compared to Q3 2024, primarily due to a 68% decrease in Light Delivery Device (LDD) sales, despite a 6% increase in Light Adjustable Lens (LAL) procedure volume.
- The company's gross margin increased to 80% in Q3 2025, up from 71% in Q3 2024, driven by a favorable shift in product mix towards LAL sales.
- RxSight reported a net loss of $(9.8) million, or $(0.24) per basic and diluted share, for Q3 2025.
- The company narrowed its full-year 2025 revenue guidance to $125.0 million to $130.0 million and raised its gross margin guidance to 76% to 77%.
- As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $227.5 million.
Nov 5, 2025, 9:11 PM
RxSight faces federal securities class action and lowered 2025 guidance
RXST
Legal Proceedings
Guidance Update
Demand Weakening
- Faruqi & Faruqi, LLP is investigating potential claims against RxSight for investors who suffered losses exceeding $75,000 between May 7, 2024, and July 8, 2025, with a deadline of September 22, 2025, to seek the role of lead plaintiff in a federal securities class action.
- The class action alleges that RxSight and its executives made false or misleading statements and/or failed to disclose "adoption challenges," overstated demand for products, and that the company was unlikely to meet its fiscal year 2025 financial guidance.
- On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in LDD sales, LAL utilization, and overall revenue, and lowered its full year 2025 guidance by approximately $42.5 million at the midpoint.
- Following this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025.
Sep 18, 2025, 11:20 PM
RxSight Faces Securities Class Action Lawsuit
RXST
Legal Proceedings
Guidance Update
Demand Weakening
- Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. (NASDAQ: RXST) and a federal securities class action has been filed, with a September 22, 2025, deadline for investors to seek the role of lead plaintiff.
- The complaint alleges that RxSight made false and/or misleading statements, failed to disclose "adoption challenges" and structural issues, overstated product demand, and was unlikely to meet its fiscal year 2025 financial guidance.
- On July 8, 2025, RxSight reported preliminary second quarter 2025 results showing significant declines in LDD sales, LAL utilization, and overall revenue, and subsequently lowered its full year 2025 guidance by approximately $42.5 million at the midpoint.
- Following this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025.
Sep 12, 2025, 3:03 PM
RxSight Securities Class Action Filed
RXST
Legal Proceedings
Guidance Update
Demand Weakening
- Faruqi & Faruqi, LLP is investigating RxSight, Inc. (NASDAQ: RXST) for potential federal securities law violations, with a lead plaintiff deadline of September 22, 2025.
- The complaint alleges that RxSight made false and/or misleading statements and failed to disclose "adoption challenges" and overstated demand, making it unlikely to meet its fiscal year 2025 financial guidance.
- These allegations follow RxSight's preliminary Q2 2025 financial results, reported on July 8, 2025, which revealed significant declines in LDD sales, LAL utilization, and overall revenue, leading to a lowered full-year 2025 guidance by approximately $42.5 million at the midpoint.
- Following this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025.
Sep 3, 2025, 3:17 PM
RxSight Faces Securities Class Action Investigation
RXST
Legal Proceedings
Guidance Update
Demand Weakening
- Faruqi & Faruqi, LLP is investigating RxSight, Inc. (NASDAQ: RXST) for alleged federal securities law violations, including making false/misleading statements and failing to disclose "adoption challenges" and structural issues.
- This investigation follows RxSight's preliminary Q2 2025 financial results, reported on July 8, 2025, which revealed significant declines in sales and utilization, prompting the company to lower its full year 2025 guidance by approximately $42.5 million at the midpoint.
- Following this news, RxSight's stock price fell $4.84, or 37.8%, to $7.95 per share on July 9, 2025.
- The deadline for investors to seek the role of lead plaintiff in the federal securities class action is September 22, 2025, for those who suffered losses exceeding $75,000 between November 7, 2024, and July 8, 2025.
Aug 28, 2025, 11:35 PM
RxSight Faces Securities Class Action Lawsuit and Investigation
RXST
Legal Proceedings
Guidance Update
Demand Weakening
- Faruqi & Faruqi, LLP is investigating potential claims and has filed a federal securities class action against RxSight, Inc. for alleged violations of federal securities laws, specifically for investors who purchased securities between November 7, 2024, and July 8, 2025.
- The complaint alleges that RxSight made false and/or misleading statements by overstating demand for its products and failing to disclose "adoption challenges" and structural issues that led to declines in sales and utilization, making it unlikely to meet its fiscal year 2025 financial guidance.
- On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results showing significant declines in LDD sales, LAL utilization, and overall revenue, and lowered its full year 2025 guidance by approximately $42.5 million at the midpoint.
- Following this news, RxSight's stock price fell $4.84, or 37.8%, to close at $7.95 per share on July 9, 2025.
- The deadline for investors to seek the role of lead plaintiff in the federal securities class action is September 22, 2025.
Aug 22, 2025, 2:25 PM
Quarterly earnings call transcripts for RxSight.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more